Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Toward Individualized Pharmaceutical Care of East Asians

Research into the relationship between genetics and drug response has focused on polymorphisms, or variations, in genes that encode drug-metabolizing enzymes, particularly the genes that affect the clearance of the anticoagulant warfarin, proton pump inhibitors, tricyclic antidepressants, and many other clinically relevant drugs. Much of this work has targeted East Asians, a genetically distinguishable and populous group. Researchers have identified polymorphisms that inactivate gene function, compared polymorphism frequencies in East-Asian and Caucasian populations, and determined the effects on the pharmacokinetic parameters of drugs. Detection in an individual of polymorphisms known to inactivate a drug-metabolizing enzyme is predictive of poor metabolism of drugs processed by that pathway, which itself may be predictive of an atypical drug response. Genetic tests can be used to screen for individuals who are poor metabolizers, with the ultimate goal of better predicting the clinical effects of drugs.

Blog Post

#TBT: Enrollment Deadline & the Role of Rx in Health Exchanges

As part of our “Throwback Thursday” blog series, we’re taking a look at a research topic that’s currently in the news and tagging it with...
Blog Post

NPC Asks CMS to Consider Patients’ Individual Treatment Effects In Part D Rulemaking

The National Pharmaceutical Council (NPC) today asked the Centers for Medicare and Medicaid Services (CMS) to consider maintaining “protected classes...
Commentary and Testimony Page

NPC Comments on CMS' Proposed Changes to Protected Classes

March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services200 Independence...
Newsletter Volume

E.V.I.dently November 2013

MessageCER Collaborative Is Assessing Evidence and Informing Decision-MakingToday we’re faced with an ever-growing availability of health information...
Press Release

NPC, UMD Study: Factors That Cause Different Treatment Responses Are Not Well Understood or Studied

Washington, DC, November 4, 2013—Although researchers and health care providers widely recognize that individuals with stage IV prostate cancer react...
Press Release

National Pharmaceutical Council Comments on PCORI Approval of Research Methodology Standards

Washington, DC (November 19, 2012)—The National Pharmaceutical Council (NPC) today commented on the Patient-Centered Outcomes Research Institute’s (...
Press Release

Leading Researchers Outline Principles for Conduct of Comparative Effectiveness Research

WASHINGTON, DC (September 11, 2012)—A new set of principles developed by a group of leading researchers could help to ensure more consistency in how...
Press Release

Pharmaceuticals Play Key Role in Achieving ACO Quality, Cost Goals

WASHINGTON, DC, July 18, 2012–As health care providers set up accountable care organizations (ACOs) and other value-based care programs,...
Commentary and Testimony Page

NPC Comments on CMS' Proposed Changes to Protected Classes

March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services200 Independence...
Commentary and Testimony Page

The Risks of Standardized Health Care

Think about the last time you visited a medical office. Even at a specialist’s office, chances are that each person waiting for his or her name to be...
Commentary and Testimony Page

Questions Abound on the Adoption of Evidence

Medical decision making should rely on evidence (when available) to ensure that treatments are appropriate and effective for patients. Given the...
Commentary and Testimony Page

Health Affairs CER Briefing Highlights Key Issues

Just one week after the appointment of the board of governors for the new comparative effectiveness research (CER) body, the Patient-Centered...
YouTube Videos

Using Distributed Data Networks to Understand Heterogeneity in Real-World Data

Kimberly Westrich, director of health services research at the National Pharmaceutical Council, explains how large observational datasets like...
YouTube Videos

Understanding Individual Patients' Health Care Needs

Paul Martino, SVP of Clinical Strategy and Innovation at WellPoint, Inc., explains that it's important for payers and other health care stakeholders...
YouTube Videos

Taking Patient Variations Into Account

Dr. Lisa Egbuonu-Davis, founder of ROI Squared, explains that data is generally designed toward looking at the mean differences instead of the...
YouTube Videos

Payer Views of Individualized Health Care

Dr. Daniel Malone, professor at the University of Arizona School of Pharmacy, explains how payers view the issue of individualized therapy. He says...
Blog Post

#TBT: Enrollment Deadline & the Role of Rx in Health Exchanges

As part of our “Throwback Thursday” blog series, we’re taking a look at a research topic that’s currently in the news and tagging it with...
Blog Post

NPC Asks CMS to Consider Patients’ Individual Treatment Effects In Part D Rulemaking

The National Pharmaceutical Council (NPC) today asked the Centers for Medicare and Medicaid Services (CMS) to consider maintaining “protected classes...
Blog Post

Relationship Between Individual Patient Differences and Health Outcomes

Despite the widely accepted fact that a patient’s biologic (e.g., age, race, genetic factors) and nonbiologic factors (e.g., social behaviors,...
Blog Post

Four Online Seminars Focus on Impact of Individual Treatment Effects on Drug Therapy

Health care decision-makers interested in understanding how heterogeneity, or individual treatment effects, impact patient health outcomes will...

Research

  •  
  • 1 of 28
  • >

Commentary & Testimony